Loading…

Cilengitide restrains the osteoclast‐like bone resorbing activity of myeloma plasma cells

Summary Cilengitide (CLG) is an inhibitor of both αvβ3 and αvβ5 integrins, with a defined anti‐tumour effect in glioblastoma. Pre‐clinical studies demonstrate its ability to restrain the bone resorbing property of metastatic osteotropic tumours and we have previously shown that the disablement of αv...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2016-04, Vol.173 (1), p.59-69
Main Authors: Tucci, Marco, Stucci, Stefania, Felici, Claudia, Cafforio, Paola, Resta, Leonardo, Rossi, Roberta, Silvestris, Franco
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4592-5c53a537e99bc329bcb1399b5a0360058cff8429acfe328f37afb210fb6447b03
cites cdi_FETCH-LOGICAL-c4592-5c53a537e99bc329bcb1399b5a0360058cff8429acfe328f37afb210fb6447b03
container_end_page 69
container_issue 1
container_start_page 59
container_title British journal of haematology
container_volume 173
creator Tucci, Marco
Stucci, Stefania
Felici, Claudia
Cafforio, Paola
Resta, Leonardo
Rossi, Roberta
Silvestris, Franco
description Summary Cilengitide (CLG) is an inhibitor of both αvβ3 and αvβ5 integrins, with a defined anti‐tumour effect in glioblastoma. Pre‐clinical studies demonstrate its ability to restrain the bone resorbing property of metastatic osteotropic tumours and we have previously shown that the disablement of αvβ3 in multiple myeloma (MM) plasma cells results in exhaustion of their in vitro osteoclast (OC)‐like activity on bone substrate. Here, we investigated the effect of CLG on this functional property of MM cells. Both αvβ3 and αvβ5 were measured on primary marrow MM cells from 19 patients, and the effect of CLG on proliferation, apoptosis and adhesion was investigated in parallel with MM cell lines and OCs from healthy donors. In addition, the effect of CLG on the capability of malignant plasma cells to produce erosive lacunae on calcium phosphate was explored in relation to the activation of intracellular kinases of molecular pathways of both integrins. Ultrastructural microscopy was used to evaluate the morphological changes in MM cells due to the effect of CLG on cell adhesion. The data from our study demonstrate that CLG restrains the bone resorbing function of MM cells by disabling their adhesion properties. Further investigations in pre‐clinical studies of osteotropic tumours are warranted.
doi_str_mv 10.1111/bjh.13922
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1785242769</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1785242769</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4592-5c53a537e99bc329bcb1399b5a0360058cff8429acfe328f37afb210fb6447b03</originalsourceid><addsrcrecordid>eNqNkL1OwzAURi0EoqUw8AIoIwxp_RM78QgVUFAlFpgYItu1W5ckLnEKysYj8Iw8CW5T2JC4w_2Wo0_3HgBOERyiMCO5XAwR4RjvgT4ijMYYJWgf9CGEaYxgkvXAkfdLCBGBFB2CHmYpzjjjffA8toWu5raxMx3V2je1sJWPmoWOnG-0U4XwzdfHZ2FfdCRdtYVcLW01j4Rq7Jtt2siZqGx14UoRrQIfQumi8MfgwIjC65NdDsDTzfXjeBJPH27vxpfTWCWU45gqSgQlqeZcKoLDkuEZLqmAhEFIM2VMlmAulNEEZ4akwkiMoJEsSVIJyQCcd72r2r2uww95af3mAlFpt_Y5SjOKE5wy_g80ZQzzDJKAXnSoqp33tTb5qralqNscwXyjPQ_a8632wJ7tatey1LNf8sdzAEYd8B50t3835Vf3k67yG9NkjVQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1776629803</pqid></control><display><type>article</type><title>Cilengitide restrains the osteoclast‐like bone resorbing activity of myeloma plasma cells</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Tucci, Marco ; Stucci, Stefania ; Felici, Claudia ; Cafforio, Paola ; Resta, Leonardo ; Rossi, Roberta ; Silvestris, Franco</creator><creatorcontrib>Tucci, Marco ; Stucci, Stefania ; Felici, Claudia ; Cafforio, Paola ; Resta, Leonardo ; Rossi, Roberta ; Silvestris, Franco</creatorcontrib><description>Summary Cilengitide (CLG) is an inhibitor of both αvβ3 and αvβ5 integrins, with a defined anti‐tumour effect in glioblastoma. Pre‐clinical studies demonstrate its ability to restrain the bone resorbing property of metastatic osteotropic tumours and we have previously shown that the disablement of αvβ3 in multiple myeloma (MM) plasma cells results in exhaustion of their in vitro osteoclast (OC)‐like activity on bone substrate. Here, we investigated the effect of CLG on this functional property of MM cells. Both αvβ3 and αvβ5 were measured on primary marrow MM cells from 19 patients, and the effect of CLG on proliferation, apoptosis and adhesion was investigated in parallel with MM cell lines and OCs from healthy donors. In addition, the effect of CLG on the capability of malignant plasma cells to produce erosive lacunae on calcium phosphate was explored in relation to the activation of intracellular kinases of molecular pathways of both integrins. Ultrastructural microscopy was used to evaluate the morphological changes in MM cells due to the effect of CLG on cell adhesion. The data from our study demonstrate that CLG restrains the bone resorbing function of MM cells by disabling their adhesion properties. Further investigations in pre‐clinical studies of osteotropic tumours are warranted.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.13922</identifier><identifier>PMID: 26728969</identifier><language>eng</language><publisher>England</publisher><subject>Apoptosis - drug effects ; bone disease ; Bone Resorption - metabolism ; Bone Resorption - pathology ; Cell Adhesion - drug effects ; Cell Proliferation - drug effects ; cilengitide ; Female ; Humans ; Integrin alphaVbeta3 - metabolism ; Male ; multiple myeloma ; Multiple Myeloma - metabolism ; Multiple Myeloma - pathology ; Neoplasm Proteins - metabolism ; osteoclasts ; Osteoclasts - metabolism ; Osteoclasts - pathology ; Plasma Cells - metabolism ; Plasma Cells - pathology ; Receptors, Vitronectin - metabolism ; Snake Venoms - pharmacology ; Tumor Cells, Cultured</subject><ispartof>British journal of haematology, 2016-04, Vol.173 (1), p.59-69</ispartof><rights>2016 John Wiley &amp; Sons Ltd</rights><rights>2016 John Wiley &amp; Sons Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4592-5c53a537e99bc329bcb1399b5a0360058cff8429acfe328f37afb210fb6447b03</citedby><cites>FETCH-LOGICAL-c4592-5c53a537e99bc329bcb1399b5a0360058cff8429acfe328f37afb210fb6447b03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26728969$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tucci, Marco</creatorcontrib><creatorcontrib>Stucci, Stefania</creatorcontrib><creatorcontrib>Felici, Claudia</creatorcontrib><creatorcontrib>Cafforio, Paola</creatorcontrib><creatorcontrib>Resta, Leonardo</creatorcontrib><creatorcontrib>Rossi, Roberta</creatorcontrib><creatorcontrib>Silvestris, Franco</creatorcontrib><title>Cilengitide restrains the osteoclast‐like bone resorbing activity of myeloma plasma cells</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>Summary Cilengitide (CLG) is an inhibitor of both αvβ3 and αvβ5 integrins, with a defined anti‐tumour effect in glioblastoma. Pre‐clinical studies demonstrate its ability to restrain the bone resorbing property of metastatic osteotropic tumours and we have previously shown that the disablement of αvβ3 in multiple myeloma (MM) plasma cells results in exhaustion of their in vitro osteoclast (OC)‐like activity on bone substrate. Here, we investigated the effect of CLG on this functional property of MM cells. Both αvβ3 and αvβ5 were measured on primary marrow MM cells from 19 patients, and the effect of CLG on proliferation, apoptosis and adhesion was investigated in parallel with MM cell lines and OCs from healthy donors. In addition, the effect of CLG on the capability of malignant plasma cells to produce erosive lacunae on calcium phosphate was explored in relation to the activation of intracellular kinases of molecular pathways of both integrins. Ultrastructural microscopy was used to evaluate the morphological changes in MM cells due to the effect of CLG on cell adhesion. The data from our study demonstrate that CLG restrains the bone resorbing function of MM cells by disabling their adhesion properties. Further investigations in pre‐clinical studies of osteotropic tumours are warranted.</description><subject>Apoptosis - drug effects</subject><subject>bone disease</subject><subject>Bone Resorption - metabolism</subject><subject>Bone Resorption - pathology</subject><subject>Cell Adhesion - drug effects</subject><subject>Cell Proliferation - drug effects</subject><subject>cilengitide</subject><subject>Female</subject><subject>Humans</subject><subject>Integrin alphaVbeta3 - metabolism</subject><subject>Male</subject><subject>multiple myeloma</subject><subject>Multiple Myeloma - metabolism</subject><subject>Multiple Myeloma - pathology</subject><subject>Neoplasm Proteins - metabolism</subject><subject>osteoclasts</subject><subject>Osteoclasts - metabolism</subject><subject>Osteoclasts - pathology</subject><subject>Plasma Cells - metabolism</subject><subject>Plasma Cells - pathology</subject><subject>Receptors, Vitronectin - metabolism</subject><subject>Snake Venoms - pharmacology</subject><subject>Tumor Cells, Cultured</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNqNkL1OwzAURi0EoqUw8AIoIwxp_RM78QgVUFAlFpgYItu1W5ckLnEKysYj8Iw8CW5T2JC4w_2Wo0_3HgBOERyiMCO5XAwR4RjvgT4ijMYYJWgf9CGEaYxgkvXAkfdLCBGBFB2CHmYpzjjjffA8toWu5raxMx3V2je1sJWPmoWOnG-0U4XwzdfHZ2FfdCRdtYVcLW01j4Rq7Jtt2siZqGx14UoRrQIfQumi8MfgwIjC65NdDsDTzfXjeBJPH27vxpfTWCWU45gqSgQlqeZcKoLDkuEZLqmAhEFIM2VMlmAulNEEZ4akwkiMoJEsSVIJyQCcd72r2r2uww95af3mAlFpt_Y5SjOKE5wy_g80ZQzzDJKAXnSoqp33tTb5qralqNscwXyjPQ_a8632wJ7tatey1LNf8sdzAEYd8B50t3835Vf3k67yG9NkjVQ</recordid><startdate>201604</startdate><enddate>201604</enddate><creator>Tucci, Marco</creator><creator>Stucci, Stefania</creator><creator>Felici, Claudia</creator><creator>Cafforio, Paola</creator><creator>Resta, Leonardo</creator><creator>Rossi, Roberta</creator><creator>Silvestris, Franco</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>201604</creationdate><title>Cilengitide restrains the osteoclast‐like bone resorbing activity of myeloma plasma cells</title><author>Tucci, Marco ; Stucci, Stefania ; Felici, Claudia ; Cafforio, Paola ; Resta, Leonardo ; Rossi, Roberta ; Silvestris, Franco</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4592-5c53a537e99bc329bcb1399b5a0360058cff8429acfe328f37afb210fb6447b03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Apoptosis - drug effects</topic><topic>bone disease</topic><topic>Bone Resorption - metabolism</topic><topic>Bone Resorption - pathology</topic><topic>Cell Adhesion - drug effects</topic><topic>Cell Proliferation - drug effects</topic><topic>cilengitide</topic><topic>Female</topic><topic>Humans</topic><topic>Integrin alphaVbeta3 - metabolism</topic><topic>Male</topic><topic>multiple myeloma</topic><topic>Multiple Myeloma - metabolism</topic><topic>Multiple Myeloma - pathology</topic><topic>Neoplasm Proteins - metabolism</topic><topic>osteoclasts</topic><topic>Osteoclasts - metabolism</topic><topic>Osteoclasts - pathology</topic><topic>Plasma Cells - metabolism</topic><topic>Plasma Cells - pathology</topic><topic>Receptors, Vitronectin - metabolism</topic><topic>Snake Venoms - pharmacology</topic><topic>Tumor Cells, Cultured</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tucci, Marco</creatorcontrib><creatorcontrib>Stucci, Stefania</creatorcontrib><creatorcontrib>Felici, Claudia</creatorcontrib><creatorcontrib>Cafforio, Paola</creatorcontrib><creatorcontrib>Resta, Leonardo</creatorcontrib><creatorcontrib>Rossi, Roberta</creatorcontrib><creatorcontrib>Silvestris, Franco</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tucci, Marco</au><au>Stucci, Stefania</au><au>Felici, Claudia</au><au>Cafforio, Paola</au><au>Resta, Leonardo</au><au>Rossi, Roberta</au><au>Silvestris, Franco</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cilengitide restrains the osteoclast‐like bone resorbing activity of myeloma plasma cells</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2016-04</date><risdate>2016</risdate><volume>173</volume><issue>1</issue><spage>59</spage><epage>69</epage><pages>59-69</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><abstract>Summary Cilengitide (CLG) is an inhibitor of both αvβ3 and αvβ5 integrins, with a defined anti‐tumour effect in glioblastoma. Pre‐clinical studies demonstrate its ability to restrain the bone resorbing property of metastatic osteotropic tumours and we have previously shown that the disablement of αvβ3 in multiple myeloma (MM) plasma cells results in exhaustion of their in vitro osteoclast (OC)‐like activity on bone substrate. Here, we investigated the effect of CLG on this functional property of MM cells. Both αvβ3 and αvβ5 were measured on primary marrow MM cells from 19 patients, and the effect of CLG on proliferation, apoptosis and adhesion was investigated in parallel with MM cell lines and OCs from healthy donors. In addition, the effect of CLG on the capability of malignant plasma cells to produce erosive lacunae on calcium phosphate was explored in relation to the activation of intracellular kinases of molecular pathways of both integrins. Ultrastructural microscopy was used to evaluate the morphological changes in MM cells due to the effect of CLG on cell adhesion. The data from our study demonstrate that CLG restrains the bone resorbing function of MM cells by disabling their adhesion properties. Further investigations in pre‐clinical studies of osteotropic tumours are warranted.</abstract><cop>England</cop><pmid>26728969</pmid><doi>10.1111/bjh.13922</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-1048
ispartof British journal of haematology, 2016-04, Vol.173 (1), p.59-69
issn 0007-1048
1365-2141
language eng
recordid cdi_proquest_miscellaneous_1785242769
source Wiley-Blackwell Read & Publish Collection
subjects Apoptosis - drug effects
bone disease
Bone Resorption - metabolism
Bone Resorption - pathology
Cell Adhesion - drug effects
Cell Proliferation - drug effects
cilengitide
Female
Humans
Integrin alphaVbeta3 - metabolism
Male
multiple myeloma
Multiple Myeloma - metabolism
Multiple Myeloma - pathology
Neoplasm Proteins - metabolism
osteoclasts
Osteoclasts - metabolism
Osteoclasts - pathology
Plasma Cells - metabolism
Plasma Cells - pathology
Receptors, Vitronectin - metabolism
Snake Venoms - pharmacology
Tumor Cells, Cultured
title Cilengitide restrains the osteoclast‐like bone resorbing activity of myeloma plasma cells
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T00%3A35%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cilengitide%20restrains%20the%20osteoclast%E2%80%90like%20bone%20resorbing%20activity%20of%20myeloma%20plasma%20cells&rft.jtitle=British%20journal%20of%20haematology&rft.au=Tucci,%20Marco&rft.date=2016-04&rft.volume=173&rft.issue=1&rft.spage=59&rft.epage=69&rft.pages=59-69&rft.issn=0007-1048&rft.eissn=1365-2141&rft_id=info:doi/10.1111/bjh.13922&rft_dat=%3Cproquest_cross%3E1785242769%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4592-5c53a537e99bc329bcb1399b5a0360058cff8429acfe328f37afb210fb6447b03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1776629803&rft_id=info:pmid/26728969&rfr_iscdi=true